AMRI (AMRI) Completes Acquisition Of Euticals

Monday, July 11, 2016

Source: BioSpace

AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered in LodiItaly, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). This completes the transaction initially announced on May 5, 2016.

The acquisition positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry, and in particular, provides the company with an established custom synthesis presence in key European markets.

"We are delighted to have Euticals join the AMRI family as we create an industry leader in global contract research and manufacturing. Euticals' API platform is a significant addition to AMRI's capabilities, and we are excited about the future opportunities our company will have as a result of this pivotal acquisition," said William S. Marth, AMRI's president and chief executive officer.

View All News »